Getinge (GETI B.ST) Stock Price

Getinge Price

OMX·CLOSED
240.50SEK-0.10 (-0.04 %)
Market closed

Revenue has compounded at 1.5% per year over the past 10 years to 34.97 B SEK. Earnings per share have grown at 3.7% per year over the last 10 years. Getinge's net margin stands at 6.5%, down from 11.0% several years earlier. Getinge currently offers a dividend yield of about 1.91%. The payout ratio is around 55% of earnings. The dividend has grown at 5.1% per year over the past 10 years. Analysts set a median price target of 231.03 SEK, implying 3.9% below the current price. Of 14 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 33% above its 52-week low.

Getinge stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Getinge over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Getinge stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Getinge's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Getinge Stock Price History
DateGetinge Price
8/19/2026240.50 SEK
8/18/2026240.60 SEK
8/17/2026239.70 SEK
8/14/2026240.10 SEK
8/13/2026239.90 SEK
8/12/2026239.00 SEK
8/11/2026239.00 SEK
8/10/2026239.20 SEK
8/7/2026237.00 SEK
8/6/2026237.70 SEK
8/5/2026238.40 SEK
8/4/2026241.00 SEK
7/31/2026237.40 SEK
7/30/2026237.00 SEK
7/29/2026238.10 SEK
7/28/2026228.60 SEK
7/27/2026230.30 SEK
7/24/2026230.30 SEK
7/23/2026228.00 SEK
7/22/2026233.20 SEK
7/21/2026232.60 SEK
7/20/2026232.00 SEK
7/17/2026231.60 SEK
7/16/2026211.10 SEK
7/15/2026206.60 SEK
7/14/2026206.80 SEK
7/13/2026208.90 SEK
7/10/2026207.70 SEK
7/9/2026203.30 SEK
7/8/2026202.30 SEK
7/7/2026206.00 SEK
7/6/2026205.90 SEK
7/3/2026206.40 SEK
7/2/2026204.80 SEK
7/1/2026202.80 SEK
6/30/2026198.10 SEK
6/29/2026197.75 SEK
6/26/2026197.55 SEK
6/25/2026199.85 SEK
6/24/2026196.20 SEK
6/23/2026192.80 SEK
6/22/2026191.65 SEK
6/18/2026192.00 SEK
6/17/2026194.45 SEK
6/16/2026194.05 SEK
6/15/2026198.05 SEK
6/12/2026194.55 SEK
6/11/2026189.15 SEK
6/10/2026191.60 SEK
6/9/2026192.50 SEK
6/8/2026191.95 SEK
6/5/2026194.35 SEK
6/4/2026194.35 SEK
6/3/2026188.90 SEK
6/2/2026185.50 SEK
6/1/2026185.60 SEK
5/29/2026189.85 SEK
5/28/2026188.50 SEK
5/27/2026192.10 SEK
5/26/2026192.65 SEK
5/25/2026197.95 SEK
5/22/2026196.25 SEK
5/21/2026196.50 SEK
5/20/2026196.95 SEK
5/19/2026195.00 SEK
5/18/2026191.75 SEK
5/15/2026189.10 SEK
5/13/2026191.50 SEK
5/12/2026190.95 SEK
5/11/2026190.65 SEK
5/8/2026188.70 SEK
5/7/2026186.90 SEK
5/6/2026187.40 SEK
5/5/2026182.30 SEK
5/4/2026182.65 SEK
4/30/2026183.55 SEK
4/29/2026185.60 SEK
4/28/2026192.40 SEK
4/27/2026194.40 SEK
4/24/2026192.05 SEK
4/23/2026194.00 SEK
4/22/2026196.00 SEK
4/21/2026198.20 SEK
4/20/2026200.90 SEK
4/17/2026203.90 SEK
4/16/2026200.90 SEK
4/15/2026199.65 SEK
4/14/2026196.35 SEK
4/13/2026191.95 SEK
4/10/2026191.95 SEK
4/9/2026191.45 SEK
4/8/2026193.75 SEK
4/7/2026190.00 SEK
4/2/2026191.20 SEK
4/1/2026193.25 SEK
3/31/2026188.55 SEK
3/30/2026187.35 SEK
3/27/2026184.50 SEK
3/26/2026187.00 SEK
3/25/2026184.80 SEK
3/24/2026183.75 SEK
3/23/2026182.05 SEK
3/20/2026180.60 SEK
3/19/2026182.50 SEK
3/18/2026186.75 SEK
3/17/2026189.60 SEK
3/16/2026188.25 SEK
3/13/2026188.95 SEK
3/12/2026190.25 SEK
3/11/2026192.70 SEK
3/10/2026194.95 SEK
3/9/2026193.40 SEK
3/6/2026197.28 SEK
3/5/2026198.53 SEK
2/27/2026202.60 SEK
2/26/2026202.13 SEK
2/25/2026198.75 SEK
2/23/2026201.70 SEK
2/20/2026201.98 SEK
2/19/2026200.44 SEK
2/18/2026199.35 SEK
2/17/2026198.02 SEK
2/16/2026197.87 SEK
2/13/2026201.18 SEK
2/12/2026199.43 SEK
2/11/2026201.01 SEK
2/10/2026205.44 SEK
2/9/2026202.43 SEK
2/6/2026204.74 SEK
2/5/2026203.86 SEK
2/4/2026203.69 SEK
2/3/2026199.67 SEK
2/2/2026196.94 SEK
1/30/2026195.71 SEK
1/29/2026196.46 SEK
1/28/2026197.15 SEK
1/27/2026201.39 SEK
1/26/2026208.63 SEK
1/23/2026211.12 SEK
1/22/2026211.72 SEK
1/21/2026209.69 SEK
1/20/2026210.21 SEK
1/19/2026213.47 SEK
1/17/2026224.06 SEK
1/16/2026220.28 SEK
1/14/2026219.75 SEK
1/13/2026219.77 SEK
1/12/2026219.39 SEK
1/9/2026226.10 SEK
1/8/2026221.14 SEK
1/7/2026225.41 SEK
1/5/2026218.23 SEK
1/2/2026219.44 SEK
12/30/2025217.90 SEK
12/29/2025216.59 SEK
12/23/2025213.30 SEK
12/22/2025211.62 SEK
12/19/2025211.78 SEK
12/18/2025211.92 SEK
12/17/2025213.40 SEK
12/16/2025214.08 SEK
12/15/2025212.45 SEK
12/12/2025209.74 SEK
12/11/2025208.18 SEK
12/10/2025206.50 SEK
12/9/2025205.00 SEK
12/8/2025207.93 SEK
12/5/2025211.20 SEK
12/4/2025210.70 SEK
12/3/2025210.15 SEK
12/2/2025211.80 SEK
12/1/2025215.82 SEK
11/28/2025215.16 SEK
11/27/2025214.82 SEK
11/26/2025213.70 SEK
11/25/2025210.71 SEK
11/24/2025208.54 SEK
11/21/2025206.57 SEK
11/20/2025207.28 SEK
11/19/2025207.78 SEK
11/18/2025207.60 SEK
11/17/2025212.20 SEK
11/14/2025216.15 SEK
11/13/2025221.08 SEK
11/12/2025221.21 SEK
11/10/2025216.12 SEK
11/7/2025216.94 SEK
11/6/2025217.83 SEK
11/5/2025219.64 SEK
11/4/2025220.65 SEK
11/3/2025222.44 SEK
10/31/2025223.58 SEK
10/30/2025224.39 SEK
10/29/2025224.67 SEK
10/28/2025223.31 SEK
10/27/2025221.22 SEK
10/24/2025223.90 SEK
10/23/2025224.10 SEK
10/22/2025223.60 SEK
10/21/2025223.62 SEK
10/20/2025216.77 SEK
10/17/2025214.40 SEK
10/16/2025212.09 SEK
10/15/2025208.88 SEK
10/14/2025206.10 SEK
10/13/2025207.64 SEK
10/10/2025206.60 SEK
10/9/2025210.07 SEK
10/8/2025211.60 SEK
10/7/2025213.50 SEK
10/6/2025213.98 SEK
10/3/2025211.30 SEK
10/2/2025209.22 SEK
10/1/2025203.98 SEK
9/29/2025202.50 SEK
9/26/2025201.50 SEK
9/25/2025199.45 SEK
9/24/2025209.71 SEK
9/23/2025214.28 SEK
9/22/2025211.66 SEK
9/19/2025210.86 SEK
9/18/2025211.37 SEK
9/17/2025211.22 SEK
9/16/2025211.60 SEK
9/15/2025213.02 SEK
9/12/2025213.81 SEK
9/11/2025212.50 SEK
9/10/2025212.04 SEK
9/9/2025212.30 SEK
9/8/2025210.67 SEK
9/5/2025209.93 SEK
9/4/2025205.66 SEK
9/3/2025204.70 SEK
9/2/2025204.40 SEK
9/1/2025209.60 SEK
8/29/2025207.19 SEK
8/28/2025208.29 SEK
8/27/2025209.40 SEK
8/26/2025209.21 SEK
8/25/2025207.89 SEK
8/22/2025206.77 SEK
Access this data via the Eulerpool API
Get Free API Key

Getinge Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
31.83 B SEK
4.15 B SEK
2.41 B SEK
Jan 1, 2024
34.76 B SEK
4.48 B SEK
1.64 B SEK
Jan 1, 2025
34.97 B SEK
4.19 B SEK
2.26 B SEK
Jan 1, 2026 (e)
35.80 B SEK
4.98 B SEK
3.36 B SEK
Jan 1, 2027 (e)
37.48 B SEK
5.52 B SEK
3.80 B SEK
Jan 1, 2028 (e)
39.41 B SEK
6.12 B SEK
4.11 B SEK
Jan 1, 2029 (e)
43.41 B SEK
6.63 B SEK
4.39 B SEK
Jan 1, 2030 (e)
43.30 B SEK
0.00 SEK
5.74 B SEK

Getinge Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 22, 2026, 12:44 AM
 
REVENUEB SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB SEK
EBITB SEK
EBIT MARGIN%
NET INCOMEB SEK
NET INCOME GROWTH%
DIV.SEK
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
30.2422.1722.5024.1726.5629.8227.0528.2931.8334.7634.9735.8037.4839.4143.4143.30
–-26.671.477.459.8812.27-9.294.6012.499.210.602.384.695.1410.17-0.26
46.8446.9047.6245.7346.9049.3750.2147.4045.5447.3347.6347.6347.6347.6347.6347.63
14.1610.4010.7111.0512.4614.7213.5813.4114.5016.4516.6517.0517.8518.7720.6820.62
3.422.682.26-0.282.704.964.473.884.154.484.194.985.526.126.63–
11.3112.0810.03-1.1710.1516.6416.5113.7213.0312.9011.9713.9114.7115.5415.27–
1.391.191.38-0.971.223.242.972.492.411.642.263.363.804.114.395.74
–-14.5315.82-170.28-226.37165.06-8.31-16.13-3.17-32.0937.8548.7213.078.196.7730.80
2.802.802.001.501.001.503.004.004.254.404.604.755.215.71––
––-28.57-25.00-33.3350.00100.0033.336.253.534.553.269.689.60––
241.78241.78250.72272.37272.37272.37272.37272.37272.37272.37272.37272.37272.37272.37272.37272.37
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Getinge generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Getinge retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Getinge's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Getinge has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Getinge's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Getinge stock margins

The Getinge margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Getinge. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Getinge.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
50.21 %
16.51 %
10.98 %
Jan 1, 2022
47.40 %
13.72 %
8.80 %
Jan 1, 2023
45.54 %
13.03 %
7.58 %
Jan 1, 2024
47.33 %
12.90 %
4.71 %
Jan 1, 2025
47.63 %
11.97 %
6.46 %
Jan 1, 2026 (e)
47.63 %
13.91 %
9.38 %
Jan 1, 2027 (e)
47.63 %
14.71 %
10.13 %
Jan 1, 2028 (e)
47.63 %
15.54 %
10.43 %

Getinge Stock Revenue, EBIT, Earnings per Share

The Getinge earnings per share therefore indicates how much revenue Getinge has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
99.31 SEK
16.40 SEK
10.90 SEK
Jan 1, 2022
103.87 SEK
14.26 SEK
9.15 SEK
Jan 1, 2023
116.85 SEK
15.23 SEK
8.86 SEK
Jan 1, 2024
127.62 SEK
16.46 SEK
6.01 SEK
Jan 1, 2025
128.39 SEK
15.37 SEK
8.29 SEK
Jan 1, 2026 (e)
131.45 SEK
18.28 SEK
12.33 SEK
Jan 1, 2027 (e)
137.61 SEK
20.25 SEK
13.94 SEK
Jan 1, 2028 (e)
144.67 SEK
22.48 SEK
15.08 SEK

Getinge business model & stock analysis

Getinge AB is a globally leading company that offers innovative solutions and products for the healthcare industry. The company was founded in Sweden in 1904 and has since had a long history in the medical technology industry. Getinge AB is known for its leading position in the field of medical equipment, including autoclaves, sterilizers, washer-disinfectors, and ventilators. The business model of Getinge AB is focused on the needs of customers in the healthcare sector. The company operates five business areas: Acute Care Therapies, Infection Control, Extended Care, Life Science, and Surgical Workflows. Each of these business areas focuses on specific needs and requirements within the healthcare sector. Getinge AB aims to offer its customers innovative and high-quality products and services worldwide. The company promotes continuous innovation and aims to leverage the potential of cutting-edge technologies in the market to develop solutions that improve the lives of patients and healthcare professionals. Various divisions and products - Acute Care Therapies: One of Getinge AB's main products in the Acute Care Therapies area is extracorporeal membrane oxygenation machines (ECMO). These systems are used to support patients with respiratory failure. Another important product line is the Intra-Aortic Balloon Pump (IABP), which is used to support patients with heart failure or cardiogenic shock. - Infection Control: In the Infection Control area, Getinge AB focuses on developing products to control infections that can be caused by hospital environments and medical instruments. This includes sterilization and disinfection devices, as well as cleaning and disinfection agents. - Extended Care: The Extended Care business area offers products and solutions for non-acute patient care. The company focuses on offering innovative products and services that contribute to improving the quality of care and reducing costs. This includes products such as patient beds, mattresses, and assistive devices. - Life Science: In the Life Science area, Getinge AB offers products and services for the biopharmaceutical industry and for research and development. The company specializes in the development of cleanroom technology, which helps make the production of medications safer and more efficient. - Surgical Workflows: The Surgical Workflows business area focuses on optimizing surgical workflows and increasing efficiency. Getinge AB offers products and services such as operating tables, anesthesia and monitoring systems, and wound care products. In summary, Getinge AB has a long history in the medical technology industry and is a leading company in the field. The company operates five business areas that focus on specific needs and requirements within the healthcare sector. Getinge AB aims to offer its customers worldwide innovative and high-quality products and services. The product range includes a wide range of innovative medical technology products, including autoclaves, sterilizers, washer-disinfectors, ventilators, cleaning and disinfection agents, and other medical technology products.

Getinge SWOT Analysis

Strengths

1. Established market presence: Getinge AB is a well-known and reputable company within the medical technology industry.

2. Diverse product portfolio: The company offers a wide range of medical devices and equipment, catering to various healthcare needs.

3. Strong research and development capabilities: Getinge invests heavily in R&D, enabling them to continuously innovate and introduce new products.

Weaknesses

1. Dependence on key markets: Getinge relies heavily on certain regions for its revenue, making it vulnerable to economic fluctuations in those markets.

2. High production costs: The company's manufacturing processes can be expensive, affecting its profit margins.

3. Limited presence in emerging markets: Getinge has relatively lower market penetration in developing countries compared to its competitors.

Opportunities

1. Increasing healthcare expenditure: As global healthcare spending continues to rise, Getinge can benefit from increased demand for medical devices and equipment.

2. Growing aging population: The aging population across the world presents an opportunity for Getinge to provide specialized healthcare solutions.

3. Expansion into emerging markets: The company can focus on expanding its presence in developing countries where there is a growing demand for healthcare solutions.

Threats

1. Intense competition: Getinge operates in a highly competitive industry, facing competition from both established players and emerging startups.

2. Stringent regulatory environment: Compliance with stringent regulations can pose challenges for Getinge in terms of product development and market approvals.

3. Technological advancements: Rapid technological advancements may make existing products obsolete, requiring continuous investment in innovation.

Getinge Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Getinge historical P/E ratio, EBIT multiple, and P/S ratio

Getinge annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Getinge shares outstanding

The number of shares of Getinge was 272.37 M in 2025. This indicates how many shares Getinge is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
272.37 M Stocks
Jan 1, 2022
272.37 M Stocks
Jan 1, 2023
272.37 M Stocks
Jan 1, 2024
272.37 M Stocks
Jan 1, 2025
272.37 M Stocks
Jan 1, 2026 (e)
272.37 M Stocks
Jan 1, 2027 (e)
272.37 M Stocks
Jan 1, 2028 (e)
272.37 M Stocks

Getinge stock splits

In Getinge's history, there have been no stock splits.

Getinge Dividend History

33 years of dividend payments · 6 consecutive increases

YearAnnual DividendYoY ChangePayments
20264.75SEKYTD—1×
Apr 22, 20264.75SEK↑ 3.3%1/1
20254.60SEK↑ 4.5%1×
Apr 23, 20254.60SEK↑ 4.5%1/1
20244.40SEK↑ 3.5%1×
20234.25SEK↑ 6.3%1×
20224.00SEK↑ 33.3%1×
20213.00SEK↑ 100.0%1×
20201.50SEK↑ 50.0%1×
20191.00SEK↓ 33.3%1×
20181.50SEK↓ 25.0%1×
20172.00SEK↓ 28.6%1×

Getinge dividend history and estimates

In 2025, Getinge paid a dividend amounting to 4.60 SEK. Dividend means that Getinge distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
3.00 SEK
0.00 SEK
Jan 1, 2022
4.00 SEK
0.00 SEK
Jan 1, 2023
4.25 SEK
0.00 SEK
Jan 1, 2024
4.40 SEK
0.00 SEK
Jan 1, 2025
4.60 SEK
0.00 SEK
Jan 1, 2026
4.75 SEK
0.00 SEK
Jan 1, 2027 (e)
0.00 SEK
5.21 SEK
Jan 1, 2028 (e)
0.00 SEK
5.71 SEK

Getinge dividend payout ratio

In 2025, Getinge had a payout ratio of 55.49%. The payout ratio indicates the percentage of the company's profits that Getinge distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
27.51 %
Jan 1, 2022
43.74 %
Jan 1, 2023
47.99 %
Jan 1, 2024
73.16 %
Jan 1, 2025
55.49 %
Jan 1, 2026 (e)
38.52 %
Jan 1, 2027 (e)
37.35 %
Jan 1, 2028 (e)
37.85 %

Current Getinge forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
5.63 %
Buy
57.14 % (8)
Hold
35.71 % (5)
Sell
7.14 % (1)
12M Price Target
231.03
Last Price
246.10
Currency
SEK
12M Return Potential
-6.12 %
LTM Return
0 %

Getinge Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/24/20242.00SEK-7.86 BSEK-2024 Q1
2/6/20243.46SEK-9.17 BSEK-2023 Q4
7/17/20232.72SEK-7.35 BSEK-2023 Q2
4/24/20232.05SEK-6.92 BSEK-2023 Q1
2/1/20234.34SEK-8.98 BSEK-2022 Q4
10/19/20222.51SEK-6.96 BSEK-2022 Q3
7/19/20222.16SEK-6.87 BSEK-2022 Q2
4/26/20222.39SEK-6.47 BSEK-2022 Q1
1/28/20223.61SEK-8.20 BSEK-2021 Q4
10/20/20212.54SEK-6.72 BSEK-2021 Q3
...

EESG©

Eulerpool ESG Scorecard© for the Getinge stock

75/100
76
Environment
80
Social
69
Governance
E

Environment

20
Scope 1 - Direct Emissions15,532
Scope 2 - Indirect emissions from purchased energy3,901
Scope 3 - Indirect emissions within the value chain614,508
Total CO₂ emissions19,433
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees38
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Getinge shareholder structure

% Name
0.99531%
Storebrand Kapitalforvaltning AS
Storebrand Kapitalforvaltning AS
0.62484%
SEB Investment Management AB
SEB Investment Management AB
0.48130%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.25716%
Danske Bank Asset Management
Danske Bank Asset Management
0.25672%
Charles Schwab Investment Management, Inc.
Charles Schwab Investment Management, Inc.
0.24777%
Skandia Investment Management AB
Skandia Investment Management AB
...

Getinge Executives and Management Board

21 members · avg. age 55 · 38 % women

MP

Mr. Mattias Perjos (53)

President, Chief Executive Officer, Director · since 2017

59.85 M SEK

Management

AP

Ms. Agneta Palmer (47)

Chief Financial Officer

–
EF

Ms. Elin Frostehav (43)

President - Acute Care Therapies

–
EH

Mr. Eric Honroth (54)

President - Life Science

–
SR

Mr. Stephane Le Roy (48)

President - Surgical Workflows

–
ML

Mr. Magnus Lundbaeck (56)

Executive Vice President - Human Resources

–
JE

Ms. Joanna Engelke (65)

Executive Vice President - Quality Compliance, Regulatory and Medical Affairs

–

Board of Directors

JM

Mr. Johan Malmquist (64)

Independent Chairman of the Board · since 1997

1.81 M SEK
DF

Mr. Dan Frohm (44)

Director

1.08 M SEK
JB

Mr. Johan Bygge (69)

Independent Director

1.02 M SEK
CW

Ms. Cecilia Wennborg (62)

Independent Director

1.01 M SEK
KS

Mr. Kristian Samuelsson (48)

Independent Director

856,600.00 SEK
CB

Mr. Carl Bennet (74)

Vice Chairman of the Board

816,600.00 SEK

Frequently asked questions about Getinge

Getinge AB is a global medical technology company that specializes in providing solutions for hospitals and healthcare organizations. The business model of Getinge AB revolves around offering innovative products, systems, and services within areas such as surgical workflows, patient care, and infection control. They strive to improve patient outcomes and enable healthcare professionals to deliver efficient and safe care. With a focus on providing high-quality medical equipment and integrated solutions, Getinge AB aims to enhance the overall healthcare experience.

Getinge AB is primarily active in the healthcare industry.

The main competitors of Getinge AB in the market include leading medical technology companies such as Medtronic, Johnson & Johnson, and Siemens Healthineers. These companies also provide a wide range of innovative medical devices and solutions, competing with Getinge AB in areas such as surgical equipment, patient handling systems, and infection control products. Getinge AB, as a global provider of medical technology, faces intense competition in its quest to deliver advanced healthcare solutions to customers worldwide.

Getinge AB, a renowned Swedish company, has a rich history and a strong background in the healthcare industry. Established in 1904, Getinge has evolved into a global leader in medical technology, providing innovative solutions for infection control and surgical workflows. With a primary focus on improving patient outcomes and enhancing healthcare efficiency, Getinge offers a wide range of products and services, including advanced medical equipment, such as surgical tables, anesthesia systems, and sterilization equipment. Over the years, Getinge has expanded its operations internationally, becoming a trusted partner for healthcare institutions worldwide. Through continuous innovation and dedication to healthcare excellence, Getinge AB has firmly established itself as a leading player in the global medical technology market.

Getinge AB has achieved several significant milestones throughout its history. One major accomplishment was the acquisition of Maquet in 2000, which expanded the company's portfolio and global reach. In 2006, Getinge AB successfully listed its shares on the Stockholm Stock Exchange, strengthening its position in the market. The company has also made substantial progress in research and development, introducing innovative medical technology solutions for healthcare professionals worldwide. Additionally, Getinge AB has focused on sustainability initiatives, committing to reducing its carbon footprint and promoting environmentally friendly practices. These milestones demonstrate Getinge AB's commitment to growth, innovation, and sustainability in the healthcare industry.

Getinge AB, a renowned global medical technology company based in Sweden, operates in multiple countries and regions worldwide. With a strong international presence, Getinge AB extends its operations across various continents, including Europe, Asia, North America, and Latin America. The company establishes its footprint in countries such as Sweden, Germany, France, the United States, China, Brazil, and many more. Through its extensive network and subsidiaries, Getinge AB serves customers across the globe, contributing to the advancement of healthcare and improving patient outcomes.

Getinge AB is committed to upholding certain values and corporate philosophy. The company believes in promoting patient safety and enhancing healthcare outcomes. They prioritize quality in their products and services, ensuring efficient and reliable medical solutions. Getinge AB strives for sustainability by minimizing the environmental impact of their operations and products. They value transparency, integrity, and accountability in their business practices. Getinge AB consistently focuses on innovation and advancement in the healthcare industry, aiming to improve patients' lives worldwide. With their dedication to their mission and values, Getinge AB continues to be a trusted and influential player in the medical technology sector.

Analysts currently set an average price target of 238.81 SEK for the Getinge stock (median: 231.03 SEK), implying -3.0 % versus the latest price. The consensus is based on 14 analyst ratings.

Getinge Analyst Price Targets 2026

14 analysts currently rate the Getinge stock: 8 recommend buying, 5 holding and 1 selling. For 2026, analysts expect Getinge to generate revenue of 35.80 B SEK and earnings per share of 12.33 SEK.

Getinge Analyst Price Targets 2026

Converted at the current exchange rate, the Getinge share trades at 21.71 EUR (240.50 SEK).

The Getinge share (GETI B.ST) is listed on 9 stock exchanges, including: Frankfurt (GTN.F), München (GTN.MU), Düsseldorf (GTN.DU), London (0GZV.L), SIX (Zürich) (GETIB.SW).

Getinge AB is a Swedish company specializing in the manufacturing of medical devices and solutions. The company operates in three main areas: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers products and services to improve patient care and enhance the efficiency and profitability of hospitals and medical facilities. They provide solutions for critical care situations, infection prevention and control, as well as for the life sciences, pharmaceutical, and food industries. Getinge also offers products and solutions for surgical workflows, including cleaning, disinfection, sterilization, and training services. The company follows a value-based healthcare model, aiming to provide value to customers by ensuring optimal patient treatment and economic responsibility. With a focus on continuous innovation, Getinge strives to meet the evolving needs of its customers as a global leader in the medical technology industry.

The expected revenue of Getinge is 35.80 B SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Getinge is 3.36 B SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Getinge is currently 19.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Getinge stock.

The price-to-sales ratio (P/S) of Getinge is currently 1.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Getinge stock.

The Eulerpool Quality Score for Getinge is 3/10.

The ISIN of Getinge is SE0000202624. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Getinge is 889714. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Getinge is GETI B.ST. The ticker symbol is used to trade Getinge shares on the stock exchange.

Over the past 12 months, Getinge paid a dividend of 4.60 SEK . This corresponds to a dividend yield of about 1.91 %. For the coming 12 months, Getinge is expected to pay a dividend of 5.21 SEK.

The current dividend yield of Getinge is 1.91 %.

Getinge pays a dividend, distributed in the months of , , , .

Getinge paid dividends every year for the past 32 years.

For the upcoming 12 months, dividends amounting to 5.21 SEK are expected. This corresponds to a dividend yield of 2.17 %.

Getinge is assigned to the 'Health' sector.

To receive the latest dividend of Getinge from amounting to 4.75 SEK, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Getinge distributed 4.4 SEK as dividends.

The dividends of Getinge are distributed in SEK.

All fundamentals and in-depth analysis of Getinge

Our stock analysis for Getinge stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Getinge. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Getinge Stock
Getinge Revenue→
Getinge Stock
Getinge Net Income→
Getinge Stock
Getinge P/E→
Getinge Stock
Getinge P/S→
Getinge Stock
Getinge EBIT→
Getinge Stock
Getinge Dividend→
Getinge Stock
Getinge Directors Dealings→
Getinge Stock
Getinge Stocks→
Getinge Stock
Getinge Market capitalization→
Getinge Stock
Getinge Debt→
Getinge Stock
Getinge Liabilities→
Getinge Stock
Getinge Equity→
Getinge Stock
Getinge AAQS→
Getinge Stock
Getinge Employees→
Getinge Stock
Getinge ROE→
Getinge Stock
Getinge ROA→
Getinge Stock
Getinge ROCE→
Getinge Stock
Getinge News→
Getinge Stock
Getinge Analyst Price Targets→

Health Stocks

GH ResearchGetein BiotechGI InnovationGesundheitswelt ChiemgauGian Life CareGerresheimerGilead SciencesGeronGinwa Enterprise GroupGeratherm MedicalGKB OphthalmicsGeoVax LabsAll Stocks A–Z →